Endo axing axomadol pain deal after Phase II failure means no payments for Grunenthal
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals is terminating its research programme and collaboration related to the development of axomadol (EN3324). Endo licensed exclusive rights to develop and market axomadol in the US and Canada from Grunenthal of Germany in February 2009.